This segment focuses on developing next-generation CAR T-cell therapies for solid tumors, leveraging Lyell's proprietary T-cell reprogramming technologies. The core of this segment lies in overcoming the limitations of current T-cell therapies, particularly T-cell exhaustion and lack of durable stemness. Research and development efforts are directed towards the Gen-R and Epi-R platforms, which aim to genetically and epigenetically reprogram T-cells, respectively. These technologies are designed to enhance T-cell persistence, tumor infiltration, and overall anti-tumor activity. The therapeutic areas targeted include non-small cell lung cancer, triple-negative breast cancer, and other solid tumor indications. The ultimate goal is to provide patients with more effective and long-lasting cancer treatments, improving patient outcomes and quality of life. This segment positions Lyell as a leader in the development of innovative cell therapies for challenging solid tumors.